Dyne Therapeutics entered into an Underwriting Agreement with Morgan Stanley & Jefferies, as representatives of the underwriters, for a public offering of 18,300,000 shares of common stock at $20.50 per share. Underwriters will purchase at $19.27 per share, and have a 30-day option to buy up to 2,745,000 additional shares. Net proceeds are expected to be about $352.1 million, or approximately $405.0 million if the option is fully exercised. Closing is expected on or about July 23, 2026, subject to customary conditions.
Agreement details:
- Agreement type: Underwriting agreement for public common stock offering
- Counterparty: Morgan Stanley & Jefferies, as representatives of the underwriters
- Signed / Effective: Jul 21 2026 / same
- Duration / Termination: Through expected closing on Jul 23 2026
- Reason: Raise capital to extend cash runway and fund programs
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.